 "Jubilant Life Sciences hits lifetime high on getting approval for Paroxetine tablets")
Jubilant Life Sciences has moved higher to its lifetime high of Rs 452, up 10% on the BSE, after the company said it has received approval Paroxetine tablets, the generic version of Paxil tablets, which is used as an antidepressant.
“The company has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Paroxetine tablets USP, 10 mg, 20 mg, 30 mg and 40 mg,” Jubilant Life Sciences said in a press release.
This is the generic version of Paxil tablets, 10 mg, 20 mg, 30 mg, and 40 mg® (of Apotex), which is used as an antidepressant, it added.
The company said, as on September 30, 2015, it had a total of 820 filings for formulations of which 391 have been approved in various regions globally. This includes 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe.
At 12:16 PM, the stock was up 8% at Rs 445 on the BSE. The trading volumes on the counter more than doubled with a combined 2.14 million shares changed hands on the BSE and NSE so far.
“The company has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Paroxetine tablets USP, 10 mg, 20 mg, 30 mg and 40 mg,” Jubilant Life Sciences said in a press release.
This is the generic version of Paxil tablets, 10 mg, 20 mg, 30 mg, and 40 mg® (of Apotex), which is used as an antidepressant, it added.
The company said, as on September 30, 2015, it had a total of 820 filings for formulations of which 391 have been approved in various regions globally. This includes 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe.
At 12:16 PM, the stock was up 8% at Rs 445 on the BSE. The trading volumes on the counter more than doubled with a combined 2.14 million shares changed hands on the BSE and NSE so far.